Biogen Idec Partners With Cardiokine On Vasopressin Antagonist For Hyponatremia
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trials of the oral drug, which will start this year, are expected to take two years to complete, Biogen says.
You may also be interested in...
Biogen Partners With LigoCyte On Anti-CD103 Target
Companies will pursue development of treatments for respiratory, gastrointestinal and autoimmune indications.
Biogen Partners With LigoCyte On Anti-CD103 Target
Companies will pursue development of treatments for respiratory, gastrointestinal and autoimmune indications.
Biogen Idec Planning Phase III Studies For Heart Failure Candidate Adentri
A1 adenosine receptor antagonist showed promise in Phase II as an addition to standard therapy for increasing sodium excretion, protecting renal function, according to JACC study.